IN2014DN08477A - - Google Patents

Info

Publication number
IN2014DN08477A
IN2014DN08477A IN8477DEN2014A IN2014DN08477A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A IN 8477DEN2014 A IN8477DEN2014 A IN 8477DEN2014A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A
Authority
IN
India
Prior art keywords
treatment
disclosed
methods
cell proliferative
proliferative disorders
Prior art date
Application number
Other languages
English (en)
Inventor
Arijit Chakravarty
Jeffrey A Ecsedy
Robert W Kleinfield
Kha N Le
Wen Chyi Shyu
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IN2014DN08477A publication Critical patent/IN2014DN08477A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN8477DEN2014 2012-03-20 2013-03-19 IN2014DN08477A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN08477A true IN2014DN08477A (zh) 2015-05-08

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8477DEN2014 IN2014DN08477A (zh) 2012-03-20 2013-03-19

Country Status (25)

Country Link
US (2) US20130303519A1 (zh)
EP (1) EP2827855B1 (zh)
JP (1) JP6373252B2 (zh)
KR (1) KR102128866B1 (zh)
CN (1) CN104271129A (zh)
AU (1) AU2013235275B2 (zh)
CA (1) CA2868024A1 (zh)
EA (1) EA036434B1 (zh)
ES (1) ES2746946T3 (zh)
GE (1) GEP20186900B (zh)
HK (1) HK1206253A1 (zh)
IL (1) IL234686B (zh)
IN (1) IN2014DN08477A (zh)
JO (1) JO3630B1 (zh)
MA (1) MA37438A1 (zh)
MX (1) MX358411B (zh)
MY (1) MY175225A (zh)
NZ (1) NZ700744A (zh)
PH (1) PH12014502109A1 (zh)
SG (2) SG10201607741RA (zh)
TN (1) TN2014000387A1 (zh)
TW (1) TWI649082B (zh)
UA (1) UA117455C2 (zh)
WO (1) WO2013142491A1 (zh)
ZA (1) ZA201407551B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP6786530B2 (ja) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. オーロラaキナーゼの選択的インヒビターに対する応答のバイオマーカー
CN110833544B (zh) * 2018-08-17 2022-08-09 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
KR19990087585A (ko) 1996-03-08 1999-12-27 돈 리사 로얄 신경학적 활성제로서의 아졸로벤즈아제핀 유도체
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60120219T2 (de) 2000-12-21 2007-04-12 Vertex Pharmaceuticals Inc., Cambridge Pyrazolverbindungen als protein-kinase-inhibitoren
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
IL159963A0 (en) 2001-08-09 2004-06-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
CA2554271A1 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
RS52436B (en) 2004-05-14 2013-02-28 Millennium Pharmaceuticals Inc. UNITS AND PROCEDURES FOR THE INHIBITION OF MITOSIS PROGRESS BY INHIBITION OF AUROR KINASE
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Cdk、gsk及びオーロラキナーゼの活性を調節するピラゾール誘導体
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
WO2007080601A1 (en) 2006-01-16 2007-07-19 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US20070238716A1 (en) 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CN101528237A (zh) 2006-10-31 2009-09-09 艾其林医药公司 艾夫他滨药物组合物
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
BR112012020557A8 (pt) * 2010-02-19 2018-01-02 Millennium Pharm Inc formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
PH12014502109A1 (en) 2014-12-10
JO3630B1 (ar) 2020-08-27
TW201343169A (zh) 2013-11-01
MY175225A (en) 2020-06-16
NZ700744A (en) 2016-09-30
CA2868024A1 (en) 2013-09-26
US10213436B2 (en) 2019-02-26
MA37438A1 (fr) 2016-05-31
EP2827855B1 (en) 2019-06-26
EP2827855A1 (en) 2015-01-28
ES2746946T3 (es) 2020-03-09
KR102128866B1 (ko) 2020-07-01
JP2015510945A (ja) 2015-04-13
JP6373252B2 (ja) 2018-08-15
MX2014011324A (es) 2014-12-05
SG11201405621UA (en) 2014-10-30
GEP20186900B (en) 2018-10-10
CN104271129A (zh) 2015-01-07
HK1206253A1 (zh) 2016-01-08
MX358411B (es) 2018-08-20
KR20140144215A (ko) 2014-12-18
US20160193224A1 (en) 2016-07-07
EA201491727A1 (ru) 2015-01-30
US20130303519A1 (en) 2013-11-14
AU2013235275B2 (en) 2017-12-07
UA117455C2 (uk) 2018-08-10
TN2014000387A1 (en) 2015-12-21
SG10201607741RA (en) 2016-11-29
IL234686B (en) 2020-01-30
EA036434B1 (ru) 2020-11-10
TWI649082B (zh) 2019-02-01
IL234686A0 (en) 2014-11-30
AU2013235275A1 (en) 2014-10-23
WO2013142491A1 (en) 2013-09-26
ZA201407551B (en) 2019-01-30

Similar Documents

Publication Publication Date Title
PH12016502066A1 (en) Methods of treating bladder cancer
MX2013007773A (es) Terapia anticancer con inhibidores duales de aurora quinasa / mek.
MX2020004986A (es) Composiciones mejoradas para tratar distrofia muscular.
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY36075A (es) Derivados de tubulisina
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA201490559A1 (ru) Композиция для лечения свища
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2019014986A (es) Formulaciones de coenzima q10 y metodos de uso.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2015013021A (es) 5-bromo-indirrubinas.
PH12014502109A1 (en) Methods of treating cancer using aurora kinase inhibitors
IN2014DN07103A (zh)
MX356102B (es) Compuestos y métodos para tratar leucemia.
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
IL235312A0 (en) Taxane compounds, preparations and methods
MX351961B (es) Analogos de diazonamida.